Genomic Determinants of Tumor Cell Dormancy in Minimal Residual Cancer Disease

Abstract

Minimal residual cancer disease refers to the small population of malignant cells that persists after apparently successful treatment and may later produce local recurrence or distant metastasis. A major biological feature of this state is tumor cell dormancy, in which viable cancer cells enter a reversible, nonproliferative or very slowly proliferative condition that permits evasion of cytotoxic therapy and immune surveillance. Genomic and epigenomic alterations influence the establishment, maintenance, and escape of dormancy through effects on cell-cycle regulation, DNA damage responses, stemness, apoptosis, metabolism, immune interaction, and adaptation to tissue microenvironments. Important determinants include alterations in TP53, RB1, CDKN2A, PI3K–AKT–mTOR signaling, RAS–MAPK pathways, estrogen or androgen receptor signaling, and genes controlling chromatin accessibility and DNA repair. However, dormancy is not determined by tumor genotype alone. Clonal selection, transcriptional plasticity, stromal signaling, extracellular matrix composition, vascular niches, inflammation, and immune editing interact to create a clinically heterogeneous residual disease state. Sensitive detection methods, including circulating tumor DNA, circulating tumor cells, methylation assays, molecular residual disease testing, and single-cell sequencing, are increasingly relevant to risk assessment. Current management remains disease-specific, but genomic characterization may support treatment escalation, prolonged maintenance, immune-based intervention, or surveillance in selected patients. Future progress will depend on integrating longitudinal molecular monitoring with functional studies and validated clinical trials designed specifically for minimal residual disease.

Introduction

Minimal residual cancer disease is the population of malignant cells that remains after surgery, radiotherapy, systemic therapy, or a combination of these interventions, despite no radiographic or clinical evidence of active disease. These cells may be present in blood, bone marrow, lymph nodes, distant organs, or protected tissue niches. Their number can be extremely low, yet their biological significance is substantial because they can remain clinically silent for years before initiating recurrence. Tumor cell dormancy provides a conceptual framework for understanding this prolonged interval between treatment and relapse.

Dormant cells are not necessarily genetically inert. They may retain stable genomic abnormalities while exhibiting a distinct transcriptional and epigenetic state. Some are intrinsically slow cycling, whereas others enter quiescence in response to stress, therapy, nutrient limitation, immune pressure, or an unfavorable microenvironment. Dormancy may therefore represent a dynamic equilibrium rather than a fixed phenotype. The genomic determinants of this state are clinically important because they may identify patients at high risk of recurrence, reveal vulnerabilities for eradication, and explain why apparently effective treatments fail to produce durable cure.

Epidemiology / Disease Burden

The burden of minimal residual disease varies according to cancer type, stage, molecular subtype, treatment sensitivity, and the sensitivity of available detection methods. Relapse after apparently curative treatment is particularly important in breast, colorectal, lung, prostate, melanoma, ovarian, and hematologic malignancies. In some cancers, recurrence occurs soon after therapy and reflects rapidly expanding resistant clones. In others, relapse may occur many years later, suggesting prolonged persistence of dormant cells.

Conventional imaging cannot reliably detect microscopic disease. Consequently, the clinical burden is often underestimated when assessed solely by radiographic recurrence. Molecular assays can identify residual tumor-derived DNA or cells before clinical relapse, although their sensitivity, specificity, and prognostic value differ among tumor types. A positive molecular residual disease result generally indicates increased relapse risk, but it does not always establish whether residual cells are actively proliferating, permanently arrested, or capable of future reactivation. This distinction is essential when considering treatment intensity and duration.

Pathophysiology

Tumor dormancy arises from interactions between cancer-cell intrinsic programs and the surrounding microenvironment. At the cellular level, dormant cells commonly show reduced activity of cyclin-dependent kinases, suppression of E2F-driven proliferation, altered RB pathway signaling, and increased reliance on stress-response mechanisms. The balance between PI3K–AKT–mTOR and RAS–MAPK signaling is particularly relevant. Strong mitogenic signaling can promote proliferation, whereas relative attenuation of these pathways may support quiescence. Changes in autophagy, oxidative phosphorylation, mitochondrial quality control, and reactive oxygen species handling can further promote survival during metabolic stress.

Genomic alterations in TP53, RB1, CDKN2A, APC, KRAS, BRAF, PIK3CA, and other pathway regulators may influence the ability of residual cells to arrest or resume growth. Their effect is context dependent. For example, loss of TP53 may permit survival after genotoxic therapy but can also create dependence on alternative checkpoint pathways. Alterations in DNA repair genes may increase mutational evolution and therapeutic sensitivity while simultaneously allowing selection of resistant subclones. Copy-number changes and structural variants can generate phenotypic diversity within the residual population.

Epigenetic regulation is equally important. DNA methylation, histone modification, nucleosome remodeling, and enhancer reprogramming can suppress proliferative genes or activate stem-like survival programs without requiring additional DNA mutations. Dormant cells may retain epigenetic plasticity that enables rapid adaptation when the microenvironment becomes favorable. Noncoding RNAs, including microRNAs and long noncoding RNAs, can regulate epithelial–mesenchymal transition, apoptosis, cell-cycle arrest, and immune evasion. These mechanisms help explain why genetically related cells may behave differently after treatment.

The microenvironment determines whether residual cells remain dormant or resume proliferation. Bone marrow niches, perivascular regions, lymphoid tissues, liver sinusoids, and fibrotic stroma can provide survival signals through integrins, extracellular matrix proteins, cytokines, growth factors, and direct cell contact. Transforming growth factor beta, interferon-related signaling, interleukins, CXCL12, and angiogenic mediators may either maintain dormancy or promote escape depending on cellular context. Immune surveillance by natural killer cells, cytotoxic T lymphocytes, macrophages, and other immune populations can restrain residual disease, but immune exhaustion, antigen loss, altered antigen presentation, and immunosuppressive myeloid cells may permit reactivation.

Risk Factors

Risk of clinically significant dormant disease is influenced by advanced stage, lymphovascular invasion, nodal involvement, aggressive histologic features, high-grade or stem-like phenotypes, incomplete treatment response, and detectable molecular residual disease. Specific genomic features associated with treatment resistance, defective apoptosis, enhanced DNA repair, epithelial–mesenchymal transition, or immune escape may increase the probability of persistence. Tumor heterogeneity is an important risk factor because a minor resistant subclone can survive treatment and later dominate the recurrent tumor.

Host factors also matter. Immunosuppression, chronic inflammation, altered metabolism, obesity, smoking-related tissue injury, and comorbid conditions may modify the residual-disease niche. Treatment-related factors include inadequate drug exposure, pharmacokinetic variability, sanctuary-site penetration, interruption of therapy, and selective pressure from sequential treatments. These factors should be interpreted together rather than used as isolated predictors.

Clinical Features

Dormant minimal residual disease is usually clinically silent. Patients may have no symptoms, normal physical examination findings, and no detectable lesion on standard imaging. When dormant cells reactivate, clinical manifestations depend on the site and biology of recurrence. Local relapse may produce pain, bleeding, obstruction, or organ-specific dysfunction, whereas metastatic recurrence can present with skeletal, neurologic, hepatic, pulmonary, or constitutional symptoms.

The interval to recurrence is biologically informative but not definitive. Early relapse often reflects residual disease with high proliferative capacity or marked treatment resistance. Late relapse may reflect prolonged dormancy, although late recurrence can also result from slow-growing disease that was simply below detection thresholds. Molecular characteristics, rather than elapsed time alone, should guide interpretation.

Diagnosis

Diagnosis of minimal residual disease requires integration of clinical assessment, pathology, imaging, and molecular testing. Circulating tumor DNA is increasingly used because it can identify tumor-specific variants or methylation patterns in plasma. Its limitations include low shedding from certain tumors, clonal hematopoiesis, assay sensitivity, and uncertainty regarding the clinical meaning of very low-level signals. Circulating tumor cells may provide cellular and phenotypic information, but technical standardization remains variable.

In hematologic malignancies, multiparameter flow cytometry, allele-specific assays, digital polymerase chain reaction, and next-generation sequencing can detect residual clones at clinically meaningful thresholds. Tissue-based sequencing may identify residual subclones and pathway alterations, while single-cell sequencing can distinguish proliferating, dormant, immune-interacting, and therapy-resistant populations. Serial testing is generally more informative than a single measurement because rising molecular burden may precede radiographic relapse.

Interpretation should be disease specific and performed within validated clinical frameworks. A molecularly positive result should not automatically trigger treatment outside evidence-based protocols. Conversely, a negative result does not prove eradication, particularly when tumor shedding is low or the assay does not capture relevant clones.

Treatment & Management

Current management is based primarily on the underlying cancer, stage, molecular subtype, prior therapy, and validated recurrence-risk models. Surgery, radiotherapy, endocrine therapy, targeted therapy, chemotherapy, immunotherapy, and maintenance treatment may all contribute to eradication or suppression of residual disease. The major therapeutic challenge is that dormant cells may be less susceptible to agents targeting DNA replication or mitosis. Prolonged exposure to treatment can suppress expansion but may also impose selection pressure and increase toxicity.

Management strategies include continued suppressive therapy, treatment intensification for molecularly positive patients, and clinical-trial enrollment. In hormone-dependent cancers, sustained endocrine blockade can limit reactivation of receptor-driven residual clones. Targeted inhibitors may be useful when a persistent actionable alteration is confirmed, although pathway redundancy and adaptive resistance remain common. Immunotherapy may be effective when residual cells retain recognizable antigens and the immune microenvironment can be reinvigorated. Combination approaches may target both tumor survival pathways and the niche that supports dormancy.

Careful surveillance remains appropriate for selected patients, particularly when the benefit of additional therapy is uncertain. Surveillance should include evidence-based clinical review and imaging, with molecular monitoring only when the assay is analytically validated and its result can influence management. Shared decision-making is essential because the psychological and physical consequences of prolonged treatment must be balanced against the probability of recurrence and the magnitude of therapeutic benefit.

Recent Advances / Emerging Therapies

Recent research is moving from static mutation profiling toward longitudinal, single-cell, and spatial analysis of residual disease. These methods can define cellular states associated with quiescence, immune evasion, metabolic adaptation, and reactivation. Functional organoid and patient-derived xenograft models may help determine whether a genomic alteration is causally involved in dormancy rather than merely associated with it.

Emerging therapeutic concepts include dormancy maintenance, dormancy disruption followed by targeted eradication, senolytic approaches, epigenetic therapy, autophagy inhibition, immune modulation, and intervention against integrin or chemokine-mediated niche interactions. The strategy of forcing dormant cells into the cell cycle may increase sensitivity to cytotoxic therapy, but it carries a risk of accelerating clinically significant relapse if eradication is incomplete. Conversely, maintaining a stable dormant state may reduce immediate risk but requires prolonged treatment and careful management of toxicity.

Minimal residual disease-guided trials are evaluating whether therapy can be escalated in molecularly positive patients or safely reduced in patients with persistently negative assays. These studies are crucial because prognostic value alone does not establish clinical utility. Future trials should incorporate genomic, epigenomic, immune, and microenvironmental biomarkers and should report long-term outcomes, quality of life, treatment-related complications, and patterns of resistance.

Guideline Recommendations

Professional guidelines generally recommend that decisions after definitive therapy be based on validated clinicopathologic risk factors and established molecular biomarkers for the specific malignancy. Molecular residual disease assays should be used when analytically validated, clinically interpretable, and supported by evidence that test results improve outcomes. Routine treatment changes based solely on an investigational assay are not generally justified outside a clinical trial.

Clinicians should document the assay used, specimen timing, limit of detection, tumor fraction, potential confounders, and whether clonal hematopoiesis could affect interpretation. Results should be reviewed in a multidisciplinary setting involving medical oncology, pathology, molecular diagnostics, radiology, and, when appropriate, genetics specialists. Patients should be informed that a positive result indicates increased risk rather than inevitable relapse, while a negative result indicates reduced detectable disease rather than guaranteed cure.

Guideline-concordant follow-up should continue regardless of molecular status. Surveillance plans should address recurrence detection, treatment toxicity, psychosocial needs, rehabilitation, reproductive health where relevant, and management of cardiovascular, metabolic, and other long-term effects of cancer therapy.

Conclusion

Tumor cell dormancy is a central mechanism through which minimal residual cancer disease persists beyond apparently successful treatment. Its biology reflects the interaction of genomic alterations, epigenetic plasticity, cellular stress responses, immune surveillance, and tissue-specific niches. Genomic profiling can identify pathways associated with persistence and reactivation, but genotype alone is insufficient to predict the behavior of residual cells. Sensitive longitudinal assays, single-cell technologies, and functional models are improving biological resolution and may enable more individualized treatment. At present, clinical decisions should remain grounded in validated disease-specific evidence, multidisciplinary interpretation, and guideline-based care. The ultimate goal is to distinguish residual cells that can safely remain controlled from those requiring eradication, while avoiding unnecessary treatment and preserving patient quality of life.